Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03667326 · ClinicalTrials.gov registry record · Phase 2
Postpartum Low-Dose Aspirin and Preeclampsia
A Phase 2 study of Preeclampsia Postpartum, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03667326: Recruiting Phase 2 study of Preeclampsia Postpartum, sponsored by Columbia University.
NCT03667326 is a Phase 2 study of Preeclampsia Postpartum that is actively recruiting participants, run by Columbia University. The registered enrollment target is 100 participants, above the 62-participant average among 8 other Preeclampsia Postpartum trials with a reported enrollment target (61% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03667326, a Phase 2 study of Preeclampsia Postpartum, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.
Primary Outcome
This is designed to measure if patients with preeclampsia with severe features diagnosed antepartum or intrapartum, will experience an increase in Flow-Mediated Dilation (FMD) - a measure of endothelial function - within 3 weeks after delivery when taking daily LDA in the postpartum period.
Conditions Studied
Interventions
- DRUG Aspirin tablet
- DRUG Placebo oral capsule
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT03667326 shows while recruiting
NCT03667326 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 62-participant average among 8 other Preeclampsia Postpartum trials with a reported enrollment target (61% higher).
The record links to 1 condition, with Preeclampsia Postpartum appearing as the primary indexed condition, and to 2 interventions - of which Aspirin tablet is the first listed.
NCT03667326 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03667326 about?
NCT03667326 is a clinical study titled "Postpartum Low-Dose Aspirin and Preeclampsia". The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia c...
What is the current status of trial NCT03667326?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2019-07-22. Estimated completion is 2026-12.
What conditions does trial NCT03667326 study?
This clinical trial studies the following conditions: Preeclampsia Postpartum.
What interventions are being tested in trial NCT03667326?
The interventions under investigation include: Aspirin tablet (DRUG), Placebo oral capsule (DRUG).
Who is sponsoring clinical trial NCT03667326?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03667326 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia Postpartum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03667326's enrollment target sits among peer trials
100 2nd of 8 the highest of 8 other Preeclampsia Postpartum trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia Postpartum trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Aspirin for Postpartum Patients With Preeclampsia
RECRUITING · Phase 2
-
Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia
RECRUITING · Early Phase 1
-
Aspirin and Preeclampsia
RECRUITING · Phase 4
-
Vascular Effects of High-Salt After Preeclampsia
RECRUITING · Early Phase 1
-
Preeclampsia Educational Program Study (PrEPS)
ACTIVE NOT RECRUITING · NA
-
MR and Inflammation After Preeclampsia
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI